LPCN Lipocine Inc.

NASDAQ
$2.11

Lipocine Inc. (LPCN) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $0.47 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.9% since its last earnings release on August 4, 2026.

Lipocine Beat Consensus Estimates
Tuesday, August 4, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 3
Tuesday · Before Open
Earnings Whisper
-
vs ($0.47)
Rev est $100K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.12

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Lipocine Inc.

Lipocine Inc is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health.

Sector

Healthcare

Industry

Drug Manufacturers/Other